Lucas Brent T. 4

What Happened
Brent T. Lucas, CEO of Envoy Medical (COCH), was granted 200,000 derivative shares (reported as an award/grant) on February 5, 2026. The grant is reported at $0.00 per share in the Form 4, indicating an equity compensation award (derivative security) rather than an open-market purchase. This is a compensation grant, not a sale; it does not by itself represent a cash purchase or immediate stock sale.

Key Details

• Transaction date: 2026-02-05; Filing date: 2026-02-09 (filing appears timely).
• Transaction type: A = Award/Grant (derivative), 200,000 shares @ $0.00.
• Shares owned after transaction: Not specified in the information provided here.
• Footnotes on vesting/exercisability:
  • F1: Options to purchase 659,811 shares vested 10/15/2023; 219,938 shares vest pro rata on the 15th of each month for 36 months.
  • F2: Some options are noted as fully exercisable.
  • F3: Options to purchase 50,000 shares vest on 2/5/2027, and 150,000 vest pro rata on the 5th of each month thereafter for 36 months.
• Transaction code context: A indicates a grant/award; these are typically equity compensation subject to vesting.

Context
This grant is a standard form of executive compensation (options or similar derivative award) with multi-year vesting conditions, meaning the shares or option exercisability will be earned over time per the footnotes. Because this is an award (not a market purchase or sale), it should be interpreted as compensation rather than a direct bullish or bearish trading signal by the insider. For derivative grants, pay attention to vesting and exercisability dates to know when the insider may be able to exercise or sell underlying shares.